Xilio Therapeutics, Inc. ( XLO) - Key Metrics
XLO Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.96 | -$0.33 | -$0.97 | -$0.97 |
| 2026Q1 | $0.08 | -$0.06 | -$0.14 | -$0.14 |
| 2025Q4 | $0.16 | $0.12 | -$0.02 | -$0.03 |
| 2025Q3 | $1.85 | -$1.58 | -$1.70 | -$1.70 |
| 2025Q2 | $2.18 | -$4.28 | -$3.91 | -$4.02 |
XLO Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -7.26 |
| 2026Q1 | 0% | -3.63 |
| 2025Q4 | 0% | 2.33 |
| 2025Q3 | 0% | -1.92 |
| 2025Q2 | 0% | -0.55 |
XLO
Price: $9.50
52 week price:
Earnings Per Share: -0.32 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 18100
Market Capitalization: 60.3 million